Alnylam Pharmace. sell Biotechhunter
Start price
31.07.20
/
50%
€125.52
Target price
06.08.20
-
Performance (%)
-3.39%
End price
06.08.20
€121.26
Summary
This prediction ended on 06.08.20 with a price of €121.26. With a performance of -3.39%, the SELL prediction for Alnylam Pharmace. by Biotechhunter was down slightly. Biotechhunter has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
AI-generated
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Alnylam Pharmace. | -2.170% | -2.170% | -47.310% | 14.328% |
| iShares Core DAX® | 0,63 % | 4,95 % | 8,66 % | 63,69 % |
| iShares Nasdaq 100 | 1,16 % | -1,16 % | 26,82 % | 89,86 % |
| iShares Nikkei 225® | 2,36 % | -1,35 % | 48,19 % | 81,68 % |
| iShares S&P 500 | 0,63 % | 1,38 % | 22,99 % | 70,25 % |